News AZ grabs licence as Ionis NASH drug heads to the clinic Could antisense drug be a fatty liver disease blockbuster?
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Roche takes on development of potential Huntington’s breakth... Ionis has completed its licensing agreement with Roche for IONIS-HTTRx, a drug which could be a breakthrough in treating Huntington’s disease.
News Alnylam soars after drug success, paving way for RNAi era Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.
News Ionis to file rare disease drug after GSK declines option Firm turns down options for inotersen and IONIS-FB-LRX.
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
